MILANO, ITALY, April 28, 2019 – Eckert Ziegler BEBIG (EZB) and Adaptiiv Medical Technologies Inc. (Adaptiiv) are pleased to announce their agreement to test and align their respective systems to provide an integrated workflow for cancer centers to create 3D printed brachytherapy applicators for use in patient specific treatment. Through this strategic collaboration, Adaptiiv and EZB will demonstrate that 3D printing can provide clinically viable solutions that improve treatment and patient care.
EZB is a European-based group active in the medical device segment of the health care industry. One of its core businesses is the production and distribution of medical products for the treatment of cancer using brachytherapy. Brachytherapy applies radioactive sources directly to or into the tumor, allowing a high dose to the tumor while sparing the surrounding healthy tissue. For the patient, this means shorter treatment periods, fewer side effects and a faster recovery.
“We are excited to collaborate with Adaptiiv and its turnkey solution for 3D printing medical accessories,” says Thomas Osche, Product Manager at EZB. “Adaptiiv is the first company to offer a platform that seamlessly integrates into existing treatment workflows and their team has demonstrated the ability to rapidly validate new approaches to treatment that are being used in a clinical setting,” says Osche.
In 2018, Adaptiiv became the first company in the world to receive US FDA 510(k) clearance for software that is intended to 3D print patient-specific medical devices for use in radiation oncology. Devices created conform to the patient anatomy to improve dose delivery, patients are more comfortable throughout the treatment period, and because the software fully integrates with treatment planning systems, setup and production times are drastically reduced. Adaptiiv’s solution represents a step further in enabling patient-specific care by increasing the clinical acceptance and implementation of 3D printing at the point-of-care.
“This is a significant milestone for us,” says Adaptiiv CTO, Alex Dunphy. “Collaborating with the team at EZB, has allowed us to continue to make significant strides towards improving the standard of care using a patient-specific approach in brachytherapy. The successful alignment of our systems will demonstrate that 3D printing can be used to provide a clinically viable solution in brachytherapy treatment. Moving forward, we are optimistic that our partnership with EZB will continue to yield solutions that lead to improved treatment and patient care.”
Adaptiiv Medical Technologies Inc. is the definitive software platform to design 3D printed medical devices for use in radiation oncology. Headquartered in Halifax, Nova Scotia, Canada, Adaptiiv is shaping the future of patient-specific healthcare through innovation and collaboration with industry leaders throughout the world. Adaptiiv has US FDA 510(k) clearance, is ISO 13485 certified, and has received a CE Mark. The company’s software is used in the United States, Canada, Australia, New Zealand, Israel, Ireland, Hong Kong, and England.
About Eckert & Ziegler BEBIG
Eckert & Ziegler BEBIG is a European-based group active in the medical device segment of the health care industry. Its core business is the production and distribution of medical products for the treatment of cancer using brachytherapy. The company headquarters are in Germany, with production facilities in Germany and in the USA, as well as offices throughout Europe, Asia and the USA. In addition, Eckert & Ziegler BEBIG has a worldwide network of distributors and agents to support the international marketing and distribution of its product line. The company’s products and equipment are intended for use by oncologists, radiotherapists, urologists, ophthalmologists and medical physicists. Eckert & Ziegler BEBIG employs approximately 145 people.
Adaptiiv Medical Technologies Inc.
+1 (902) 442-9091
Eckert & Ziegler BEBIG
Tel.: +49-30-94 10 84 0